title: [Meningococcal serogroup B vaccines].
abstract: The diversity and antigenic variability of Neisseria meningitidis serogroup B strains around the world has been a major challenge to developing a vaccine with broad coverage. Outer-membrane vesicle vaccines appear to be safe and effective but are strain-specific vaccines and used in delimited areas. Also, recombinant protein vaccines such as factor H binding protein, given alone or in combination with others antigens have been developed and may be effective against the majority of group B strains.
authors.affiliation: Centre Hospitalier de Versailles, 177, rue de Versailles, 78150 Le Chesnay, France. madommergues@orange.fr
authors.forename: M-A
authors.initials: MA
authors.lastname: Dommergues
mesh_terms: D000940:Antigenic Variation; D001425:Bacterial Outer Membrane Proteins / Q000235:genetics / Q000276:immunology*; D017242:Complement Factor H / Q000235:genetics / Q000276:immunology*; D051056:Complement Inactivating Agents / Q000276:immunology*; D006801:Humans; D008585:Meningitis, Meningococcal / Q000517:prevention & control*; D008589:Meningococcal Infections / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D038541:Neisseria meningitidis, Serogroup B / Q000235:genetics / Q000276:immunology*; D016896:Treatment Outcome; D014611:Vaccination / Q000379:methods; D017778:Vaccines, Combined / Q000008:administration & dosage
chemical_list: D001425:Bacterial Outer Membrane Proteins; D051056:Complement Inactivating Agents; D022401:Meningococcal Vaccines; D017778:Vaccines, Combined; D017242:Complement Factor H